226 related articles for article (PubMed ID: 25893294)
1. Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.
Gibaja V; Shen F; Harari J; Korn J; Ruddy D; Saenz-Vash V; Zhai H; Rejtar T; Paris CG; Yu Z; Lira M; King D; Qi W; Keen N; Hassan AQ; Chan HM
Oncogene; 2016 Feb; 35(5):558-66. PubMed ID: 25893294
[TBL] [Abstract][Full Text] [Related]
2. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
3. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
4. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
McCabe MT; Graves AP; Ganji G; Diaz E; Halsey WS; Jiang Y; Smitheman KN; Ott HM; Pappalardi MB; Allen KE; Chen SB; Della Pietra A; Dul E; Hughes AM; Gilbert SA; Thrall SH; Tummino PJ; Kruger RG; Brandt M; Schwartz B; Creasy CL
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2989-94. PubMed ID: 22323599
[TBL] [Abstract][Full Text] [Related]
5. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
Knutson SK; Wigle TJ; Warholic NM; Sneeringer CJ; Allain CJ; Klaus CR; Sacks JD; Raimondi A; Majer CR; Song J; Scott MP; Jin L; Smith JJ; Olhava EJ; Chesworth R; Moyer MP; Richon VM; Copeland RA; Keilhack H; Pollock RM; Kuntz KW
Nat Chem Biol; 2012 Nov; 8(11):890-6. PubMed ID: 23023262
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?
Dubois S; Mareschal S; Picquenot JM; Viailly PJ; Bohers E; Cornic M; Bertrand P; Veresezan EL; Ruminy P; Maingonnat C; Marchand V; Lanic H; Penther D; Bastard C; Tilly H; Jardin F
Oncotarget; 2015 Jun; 6(18):16712-24. PubMed ID: 25762637
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.
Song X; Zhang L; Gao T; Ye T; Zhu Y; Lei Q; Feng Q; He B; Deng H; Yu L
Biomed Pharmacother; 2016 Jul; 81():288-294. PubMed ID: 27261606
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
Yap DB; Chu J; Berg T; Schapira M; Cheng SW; Moradian A; Morin RD; Mungall AJ; Meissner B; Boyle M; Marquez VE; Marra MA; Gascoyne RD; Humphries RK; Arrowsmith CH; Morin GB; Aparicio SA
Blood; 2011 Feb; 117(8):2451-9. PubMed ID: 21190999
[TBL] [Abstract][Full Text] [Related]
9. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.
Baker T; Nerle S; Pritchard J; Zhao B; Rivera VM; Garner A; Gonzalvez F
Oncotarget; 2015 Oct; 6(32):32646-55. PubMed ID: 26360609
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.
Qi W; Chan H; Teng L; Li L; Chuai S; Zhang R; Zeng J; Li M; Fan H; Lin Y; Gu J; Ardayfio O; Zhang JH; Yan X; Fang J; Mi Y; Zhang M; Zhou T; Feng G; Chen Z; Li G; Yang T; Zhao K; Liu X; Yu Z; Lu CX; Atadja P; Li E
Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21360-5. PubMed ID: 23236167
[TBL] [Abstract][Full Text] [Related]
11. EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.
Bradley WD; Arora S; Busby J; Balasubramanian S; Gehling VS; Nasveschuk CG; Vaswani RG; Yuan CC; Hatton C; Zhao F; Williamson KE; Iyer P; Méndez J; Campbell R; Cantone N; Garapaty-Rao S; Audia JE; Cook AS; Dakin LA; Albrecht BK; Harmange JC; Daniels DL; Cummings RT; Bryant BM; Normant E; Trojer P
Chem Biol; 2014 Nov; 21(11):1463-75. PubMed ID: 25457180
[TBL] [Abstract][Full Text] [Related]
12. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.
Brooun A; Gajiwala KS; Deng YL; Liu W; Bolaños B; Bingham P; He YA; Diehl W; Grable N; Kung PP; Sutton S; Maegley KA; Yu X; Stewart AE
Nat Commun; 2016 Apr; 7():11384. PubMed ID: 27122193
[TBL] [Abstract][Full Text] [Related]
13. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
[TBL] [Abstract][Full Text] [Related]
14. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
Barsotti AM; Ryskin M; Zhong W; Zhang WG; Giannakou A; Loreth C; Diesl V; Follettie M; Golas J; Lee M; Nichols T; Fan C; Li G; Dann S; Fantin VR; Arndt K; Verhelle D; Rollins RA
Oncotarget; 2015 Feb; 6(5):2928-38. PubMed ID: 25671303
[TBL] [Abstract][Full Text] [Related]
16. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.
Garapaty-Rao S; Nasveschuk C; Gagnon A; Chan EY; Sandy P; Busby J; Balasubramanian S; Campbell R; Zhao F; Bergeron L; Audia JE; Albrecht BK; Harmange JC; Cummings R; Trojer P
Chem Biol; 2013 Nov; 20(11):1329-39. PubMed ID: 24183969
[TBL] [Abstract][Full Text] [Related]
17. A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
Ott HM; Graves AP; Pappalardi MB; Huddleston M; Halsey WS; Hughes AM; Groy A; Dul E; Jiang Y; Bai Y; Annan R; Verma SK; Knight SD; Kruger RG; Dhanak D; Schwartz B; Tummino PJ; Creasy CL; McCabe MT
Mol Cancer Ther; 2014 Dec; 13(12):3062-73. PubMed ID: 25253781
[TBL] [Abstract][Full Text] [Related]
18. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
[TBL] [Abstract][Full Text] [Related]
20. A687V EZH2 is a gain-of-function mutation found in lymphoma patients.
Majer CR; Jin L; Scott MP; Knutson SK; Kuntz KW; Keilhack H; Smith JJ; Moyer MP; Richon VM; Copeland RA; Wigle TJ
FEBS Lett; 2012 Sep; 586(19):3448-51. PubMed ID: 22850114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
